Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview August 2020 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and resu ...

Xencor Inc (NASDAQ:XNCR) Q2 2020 Results Conference Call August 4, 2020 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co. Jonathan Chang - SVB Leerink Mara Goldstein - Mizuho Securities Arlinda Lee - Canaccord Genuity Tom Shrader - BTIG Peter Lawso ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation or Organization) 111 West Lemon Avenue, Monrovia, CA 91016 (Address of Principal Executive Offices) (Zip Code) (626) 305-5900 ☒ QUARTERLY REPORT ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications and IR Bassil Dahiyat - President and CEO John Kuch - SVP and CFO Allen Yeng - SVP and Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Arlinda Lee - Canaccord Gabriel Fung - Mizuho Securities Ed Tenthoff - Piper Jaffray Etzer Darout - Guggenheim Securities Operator Ladies and gentlemen, thank you for stan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation or Or ...

Xencor, Inc. (NASDAQ:XNCR) Q4 2019 Earnings Conference Call February 24, 2020 4:30 PM ET Corporate Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Kuch - Senior Vice President & Chief Financial Officer Allen Yeng - Chief Medical Officer Conference Call participants Alethia Young - Cantor Fitzgerald Ted Tenthoff - Piper Jaffray Mara Goldstein - Mizuho Gregory Renzo - RBC Capital Markets Arlinda ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Or ...

Antibodies by Design™ XmAb® Antibody Therapeutics Corporate Overview November 2019 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Xencor's development plans and timelines; potential regulatory actions; expected use of cash resources; the timing and re ...

Xencor, Inc. (NASDAQ:XNCR) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer John Kuch - Senior Vice President, Finance & Chief Financial Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Etzer Darout - Guggenheim Securities Shanshan Xu - Berenberg Capital Market Mara Goldstein - Mizuho David Ruch - SVB Leerink Ar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-1622502 (State or Other Jurisdiction of Incorporation o ...